Preferred Label : lactones;
MeSH definition : Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure.
Large cyclic lactones of over a dozen atoms are MACROLIDES.;
MeSH synonym : Lactone;
MeSH annotation : pyran-2-ones: index PYRONES LACTONES but BENZOPYRAN-2-ONES is available; for cyclic
lactones over 12 atoms consider MACROLIDES;
Wikipedia link : https://en.wikipedia.org/wiki/Lactone;
Is substance : O;
Origin ID : D007783;
UMLS CUI : C0022947;
Allowable qualifiers
Currated CISMeF NLP mapping
Indexing information
Record concept(s)
Related MeSH Supplementary Concept(s)
- 14-benzyloxymethoxy-10,12-O-carbonyl-4-N-imidazolylcarbonyl-6,7-isopropylidene-3,5,7,9,11,13-hexamethylhexadec-1-ene-4,6,7,10,12,14-hexol [MeSH Supplementary Concept]
- 7,8,9,16-tetrahydroxy-14-methoxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-benzo(c)(1)oxacyclotetradecin-1-one [MeSH Supplementary Concept]
- A26771B [MeSH Supplementary Concept]
- AA 57 [MeSH Supplementary Concept]
- AA005 [MeSH Supplementary Concept]
- BK223 C [MeSH Supplementary Concept]
- ChlA-F [MeSH Supplementary Concept]
- DU 6622 [MeSH Supplementary Concept]
- F1012-2 [MeSH Supplementary Concept]
- FD 211 [MeSH Supplementary Concept]
- HP-136 [MeSH Supplementary Concept]
- KF33955 [MeSH Supplementary Concept]
- KF58333 [MeSH Supplementary Concept]
- M 230B [MeSH Supplementary Concept]
- NG 011 [MeSH Supplementary Concept]
- NVP018 [MeSH Supplementary Concept]
- TMC 34 [MeSH Supplementary Concept]
- UK 2A [MeSH Supplementary Concept]
- UK 2B [MeSH Supplementary Concept]
- UK 2C [MeSH Supplementary Concept]
- UK 2D [MeSH Supplementary Concept]
- UK-3A [MeSH Supplementary Concept]
- USF 19A [MeSH Supplementary Concept]
- YSE028 [MeSH Supplementary Concept]
- YW 3548 [MeSH Supplementary Concept]
- amberin [MeSH Supplementary Concept]
- asimin [MeSH Supplementary Concept]
- azerin [MeSH Supplementary Concept]
- intybin [MeSH Supplementary Concept]
- iresin [MeSH Supplementary Concept]
- itrabin [MeSH Supplementary Concept]
- ivalin [MeSH Supplementary Concept]
- leudrin [MeSH Supplementary Concept]
- mosin B [MeSH Supplementary Concept]
- mosin C [MeSH Supplementary Concept]
- mucocin [MeSH Supplementary Concept]
- muconin [MeSH Supplementary Concept]
- pavonin [MeSH Supplementary Concept]
- phomol [MeSH Supplementary Concept]
- stegane [MeSH Supplementary Concept]
- strigol [MeSH Supplementary Concept]
- upial [MeSH Supplementary Concept]
- xerulin [MeSH Supplementary Concept]
- yukonin [MeSH Supplementary Concept]
Semantic type(s)
UMLS correspondences (same concept)
Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure.
Large cyclic lactones of over a dozen atoms are MACROLIDES.
https://www.medg.fr/addiction-au-ghb-ghl
2018
France
teaching material
scientific and technical information
gamma-Hydroxybutyrate
Addiction
dependent drug abuse
lactones
sodium oxybate
behavior, addictive
---
http://www.cochrane.org/fr/CD007654/les-effets-long-terme-des-medicaments-amaigrissants-chez-les-personnes-presentant-une-elevation-de
2016
false
United Kingdom
France
French
meta-analysis
treatment outcome
hypertension
anti-obesity agents
overweight
appetite depressants
lactones
sibutramine
piperidines
pyrazoles
cyclobutanes
french abstract
Rimonabant
Orlistat
---
https://www.ema.europa.eu/medicines/human/EPAR/Zontivity
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
vorapaxar
vorapaxar
vorapaxar
platelet aggregation inhibitors
platelet aggregation inhibitors
administration, oral
receptor, par-1
receptors, thrombin
atherosclerosis
thrombosis
Atherothrombosis
myocardial infarction
stroke
adult
drug therapy, combination
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Product containing vorapaxar in oral dose form (medicinal product form)
lactones
pyridines
lactones
pyridines
---
https://www.has-sante.fr/portail/jcms/c_2579446/fr/zontivity-vorapaxar-antiagregant-plaquettaire
2015
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
drug therapy, combination
vorapaxar
vorapaxar
vorapaxar
adult
myocardial infarction
platelet aggregation inhibitors
platelet aggregation inhibitors
aspirin
Atherothrombosis
Atherothrombosis prophylaxis
atherosclerosis
thrombosis
Product containing vorapaxar in oral dose form (medicinal product form)
lactones
pyridines
lactones
pyridines
Clopidogrel
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=127969&nom=Lactone+de+l%27acide+4-hydroxyheptanoïque+(gamma-)
Canada
toxicological data sheet
lactones
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=171157&nom=Lactone+de+l%27acide+hydroxydécanoïque+(gamma-)
Canada
toxicological data sheet
lactones
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=127449&nom=Lactone+de+l%27acide+5-hydroxyoctanoïque
Canada
toxicological data sheet
lactones
---
http://www.cochrane.org/fr/CD004604
2010
false
true
false
United Kingdom
France
lactones
sulfones
review of literature
french abstract
adult
pain, postoperative
rofecoxib
acute pain
---
http://www.cochrane.org/fr/CD003685
2010
false
true
false
United Kingdom
France
lactones
sulfones
treatment outcome
review of literature
french abstract
arthritis, rheumatoid
rofecoxib
---
http://www.cochrane.org/fr/CD005115
2008
false
true
false
United Kingdom
France
lactones
sulfones
treatment outcome
meta-analysis
french abstract
rofecoxib
osteoarthritis
---
https://ansm.sante.fr/uploads/2021/03/11/a3285fe42fb091c553160cae4a578bd0.pdf
2005
false
France
French
Contraindications, Procedure
risk assessment
anti-inflammatory agents, non-steroidal
sulfonamides
drug tolerance
lactones
sulfonamides
lactones
france
treatment outcome
anti-inflammatory agents, non-steroidal
anti-inflammatory agents, non-steroidal
rheumatology
drug evaluation
drug utilization review
lactones
cyclooxygenase inhibitors
sulfonamides
drug interactions
popular works
practice guideline
evaluation studies
Contraindications, Drug
---